/
Neurology
Encephalitis
20
Pipeline Programs↗
20
Active Trials↗
15
Companies Involved↗
Encephalitis is an emerging landscape with 20 programs across 15 companies. The most active players are Arialys Therapeutics. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical14
Phase 1
No programs
Phase 25
Phase 31
Approved
No programs
Analysis
Modality Breakdown
72%
Small molecule
13 of 18 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 18 classified programs, each share of the total. Modality classified for 90% of 20 pipeline programs.
Analysis
Trial Status
115
clinical trials
Completed74 · 64%
Unknown status15 · 13%
Recruiting11 · 10%
Active, not recruiting5 · 4%
Not yet recruiting4 · 3%
Withdrawn3 · 3%
Other3 · 3%
Clinical Trials
Trial Activity
115 trials
Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
Recruiting·—·Phase 2·NCT06510283·10 enrolled
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)